億帆醫藥(002019.SZ):上半年淨利潤預增126.39%–157.68%
格隆匯7月11日丨億帆醫藥(002019.SZ)公佈2024年半年度業績預吿,報吿期歸屬於上市公司股東的淨利潤盈利2.46億元–2.80億元,比上年同期增長126.39%–157.68%;扣除非經常性損益後的淨利潤盈利1.75億元–1.96億元,比上年同期增長85.86%–108.42%;基本每股收益盈利0.20元/股–0.23元/股。
預計2024年上半年度歸屬於上市公司股東的淨利潤比上年同期上升較大的主要原因系本報吿期內公司新增及原有醫藥自有產品(含進口)完成市場初步佈局,使得銷售毛利增長幅度大於費用增長幅度,以及取得與收益相關政府補助同比增加所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.